Company Overview
Stereotaxis, Inc. operates within the healthcare sector, specifically focusing on the medical instruments and supplies industry, where it designs, manufactures, and markets robotic systems, instruments, and information systems for interventional laboratories in the United States and internationally. The company's core product offerings include robotic magnetic navigation (RMN) systems, such as the Genesis RMN, which are engineered to assist physicians in completing complex procedures with enhanced precision. This specialized position within the medical device market reflects a focus on advanced technological integration in clinical settings, distinguishing the firm from traditional equipment manufacturers. Currently, the company maintains a market capitalization of $180.88M and generates $32.38M in annual revenue supported by a workforce of 131 employees. These valuation and revenue figures indicate that Stereotaxis is a mid-sized enterprise within its niche, possessing a significant but not dominant market share, which suggests the company is in a growth phase where scaling operations and technology adoption are critical for expanding its revenue base beyond current levels.
Financial Health
The company reported a total revenue of $32.38M over the trailing twelve months, yet it recorded a net income loss of $22,914,000 and an EBITDA of $-18,386,000, highlighting a substantial gap between top-line growth and profitability. This disparity reveals a cost structure characterized by high operating expenses relative to sales, likely driven by research and development costs, manufacturing overhead, and the capital-intensive nature of producing robotic medical systems. Additionally, the firm generated negative free cash flow of $-6,669,125, which indicates that cash outflows from operations and investing activities exceeded cash inflows, suggesting limited financial flexibility in the short term without external financing or improved operational efficiency. Margin analysis further elucidates the financial pressures: a gross margin of 52.7% demonstrates efficient production and pricing power, whereas the operating margin of -61.2% and profit margin of -66.8% confirm that structural costs are eroding earnings before interest and taxes as well as the bottom line. On the balance sheet side, the company holds $13.42M in cash against $5.44M in debt, resulting in a debt-to-equity ratio of 29.04, which implies a leveraged position where equity is significantly smaller than the debt load, though the cash reserve provides a buffer against immediate obligations. Liquidity is supported by a current ratio of 1.51, indicating that the company possesses sufficient current assets to cover its short-term liabilities with a comfortable margin. Finally, the return on equity stands at -143.6% and the return on assets is -25.2%, metrics that reveal that management effectiveness is currently challenged by significant losses, as the firm is not generating positive returns on the capital invested by shareholders or utilized in its asset base.
Valuation Assessment
Valuation metrics for Stereotaxis, Inc. present a complex picture due to its lack of consistent profitability, with a trailing P/E ratio listed as N/A and a forward P/E of -15.18. The negative forward P/E implies that the market is pricing in future earnings that are currently projected to be negative, reflecting uncertainty about when the company will achieve sustained profitability. The price-to-book ratio is elevated at 13.19, suggesting that the market assigns a significant premium to the company's intellectual property and growth potential relative to its net asset value. Alternative valuation metrics such as a price-to-sales ratio of 5.59 and an EV/EBITDA of -9.69 further indicate that the stock is being valued on revenue multiples and enterprise value assumptions rather than traditional earnings-based multiples. In terms of trading range, the 52-week high is $3.59 and the 52-week low is $1.54, meaning the stock has experienced considerable volatility within this specific price band. The beta of 1.40 indicates that the stock price is expected to be 40% more volatile than the broader market, reflecting the high-risk profile associated with early-stage medical device development and commercialization.
Growth & Income
Revenue growth for the company is robust at 36.3% year-over-year, while earnings growth is N/A due to the company reporting a net loss, which implies that top-line expansion is occurring without corresponding immediate improvements in profitability. Since the company is not a dividend payer, there is no dividend yield or payout ratio, and the payout ratio is recorded as 0.0%, indicating that the firm retains all earnings to reinvest into growth initiatives rather than distributing income to shareholders. This reinvestment strategy is typical for companies in the development or early commercialization phase where capital is required to fund further research, expand market reach, and reduce the losses contributing to the negative net income. The overall growth and income profile is defined by rapid revenue expansion coupled with significant cash burn and a lack of dividend income, positioning the investment as a pure play on the company's ability to transition from growth to profitability in the future.